Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

SNAREs and Membrane Fusion01:43

SNAREs and Membrane Fusion

13.3K
Once a transport vesicle has recognized its target organelle, the vesicular membrane needs to fuse with the target membrane to unload the cargo. Transmembrane proteins called SNAREs present on organelle membranes and their vesicles, mediate vesicle fusion.
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
13.3K
Tagging and Fusion Proteins01:24

Tagging and Fusion Proteins

8.7K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
8.7K
Fusion of Secretory Vesicles with the Plasma Membrane01:26

Fusion of Secretory Vesicles with the Plasma Membrane

19.3K
Proteins and neurotransmitters in secretory vesicles can be released from a cell upon vesicle docking, priming, and fusion with the plasma membrane. Vesicles are docked and primed in preparation for the quick exocytosis of their contents in response to a stimulus. The fusion process is mainly carried out by a SNAP Receptor or SNARE complex, consisting of synaptobrevin, syntaxin-1, and SNAP-25.
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
19.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Posaconazole-induced gynaecomastia in a patient with COVID-19-associated mucormycosis: a case report.

Hong Kong medical journal = Xianggang yi xue za zhi·2025
Same author

Efficacy of oral modafinil on accelerating consciousness recovery in adult patients with moderate to severe acute traumatic brain injury admitted to intensive care unit: a randomized double-blind clinical trial.

Neurosurgical review·2024
Same author

A longitudinal study of interprofessional education experiences among health professional graduates.

Advances in health sciences education : theory and practice·2024
Same author

Prospects for the application of Müller glia and their derivatives in retinal regenerative therapies.

Progress in retinal and eye research·2021
Same author

S-factor of <math></math> reaction at low-energies.

Results in physics·2018
Same author

Systematic review with meta-analysis: association between acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) and risk of Crohn's disease and ulcerative colitis exacerbation.

Alimentary pharmacology & therapeutics·2018
Same journal

Fiber and continuum scale contributions to the intrinsic and apparent fracture of soft collagenous tissue <i>via</i> cutting.

Biomaterials science·2026
Same journal

Surface morphology-regulated tissue adhesion in solid and mesoporous silica-reinforced gelatin nanocomposite hydrogels.

Biomaterials science·2026
Same journal

Nanostructured hyaluronic acid-chia mucilage film as bioactive wound dressings for accelerated skin regeneration.

Biomaterials science·2026
Same journal

Tunable bio-inspired hybrid hydrogels reprogram stem cell-derived extracellular vesicles for superior wound regeneration.

Biomaterials science·2026
Same journal

Bioorthogonally reinforced injectable granular hydrogels synergizing ECM mimicry with microporosity for skin tissue engineering.

Biomaterials science·2026
Same journal

Modeling a hypoxia-integrated glioblastoma microenvironment to mimic tumor heterogeneity and chemoresistance.

Biomaterials science·2026
See all related articles

Related Experiment Video

Updated: Mar 22, 2026

A Cre-Lox P Recombination Approach for the Detection of Cell Fusion In Vivo
08:13

A Cre-Lox P Recombination Approach for the Detection of Cell Fusion In Vivo

Published on: January 4, 2012

19.7K

Fc-fusion mimetics.

H Khalili1, P T Khaw, S Brocchini

  • 1UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK. h.khalil@uel.ac.uk steve.brocchini@ucl.ac.uk.

Biomaterials Science
|April 30, 2016
PubMed
Summary
This summary is machine-generated.

A novel Fc-fusion mimetic, RpR 2, shows higher affinity for VEGF than aflibercept due to slower dissociation. This suggests potential for stable, organ-specific therapeutics.

More Related Videos

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.4K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Related Experiment Videos

Last Updated: Mar 22, 2026

A Cre-Lox P Recombination Approach for the Detection of Cell Fusion In Vivo
08:13

A Cre-Lox P Recombination Approach for the Detection of Cell Fusion In Vivo

Published on: January 4, 2012

19.7K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.4K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Area of Science:

  • Biochemistry
  • Drug Development
  • Protein Engineering

Background:

  • Development of novel biologics targeting vascular endothelial growth factor (VEGF).
  • Exploration of Fc-fusion protein alternatives for enhanced therapeutic properties.
  • Utilizing polyethylene glycol (PEG) for protein conjugation and modification.

Discussion:

  • The Fc-fusion mimetic RpR 2 was engineered using disulfide bridging with PEG as an Fc replacement.
  • RpR 2 exhibits superior binding affinity to VEGF compared to the established therapeutic aflibercept.
  • This enhanced affinity is attributed to a significantly slower dissociation rate, prolonging drug action.

Key Insights:

  • RpR 2 demonstrates improved pharmacodynamic properties over aflibercept.
  • Slower dissociation kinetics are crucial for sustained therapeutic effect at the target site.
  • The PEGylated RpR 2 mimetic represents a promising advancement in VEGF-targeted therapy.

Outlook:

  • RpRs hold significant potential for developing stable, organ-specific therapeutics.
  • Further research into RpR 2's efficacy and safety profile is warranted.
  • This approach could pave the way for next-generation VEGF inhibitors.